Allopurinol Effect on Values of Lipid Profile Fractions in Hyperuricemic Patients Diagnosed with Metabolic Syndrome

SUBJECT The concentration of serum uric acid (SUA) is one of the potential markers of cardiovascular and cerebrovascular diseases, as well as some other severe diseases. In this pharmacological - clinical study we evaluated allopurinol effect on certain values of lipid profile fractions in hyperuricemic patients diagnosed with metabolic syndrome that had pronounced cardiovascular problems, also with diagnosed hypertension. METHODS Research sample comprised 40 clinically treated hyperuricemic patients of both sexes, different ages, classified into several subgroups according to the disease diagnoses. The methods used in the study included: assay analysis, statistical and comparative methods. All clinical measurements were performed with standard IFCC methods on suitable biochemical analyzers. RESULTS Study established that after the first three months of allopurinol use, there was statistically significant difference in the average value of uric acid compared to the patients' initial state. During the next three months of therapy no further statistically significant difference in average values of uric acid (p = 0,936) was detected, meaning that the desirable effects of drug use were achieved. Simultaneously, the values of triglycerides, cholesterol and LDL fractions in test subjects increased significantly (p > 0,05). The values of HDL fractions increased after three month therapy with allopurinol, but later their value remained constant. Atherogenic index increased significantly after three and six months of therapy, therewith retaining at upper limit of reference value. CONCLUSION The study results confirmed the primary hypothesis, which was that the allopurinol use affects the values of lipid profile fractions in hyperuricemic patients.